Aldeyra Therapeutics (ALDX) Projected to Post Earnings on Thursday

Key Points

• Aldeyra Therapeutics is expected to announce its Q2 2025 earnings with analysts predicting a loss of ($0.24) per share before the market opens on August 7th.
• The stock recently opened at $5.05, with a 12-month range between $1.14 and $7.20, and analysts have set price targets ranging from $9.00 to $10.00.
• Institutional investors have shown significant interest in Aldeyra, with notable increases in positions from firms like Acadian Asset Management and AQR Capital Management, now owning a combined 59.71% of the company.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Aldeyra Therapeutics to post earnings of ($0.24) per share for the quarter.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08. On average, analysts expect Aldeyra Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aldeyra Therapeutics Price Performance

ALDX stock traded down $0.18 during midday trading on Friday, reaching $4.81. The stock had a trading volume of 1,511,276 shares, compared to its average volume of 1,161,745. The company's fifty day simple moving average is $3.82 and its 200 day simple moving average is $4.23. The company has a current ratio of 6.49, a quick ratio of 6.49 and a debt-to-equity ratio of 0.24. The company has a market cap of $288.12 million, a price-to-earnings ratio of -4.96 and a beta of 0.76. Aldeyra Therapeutics has a 52-week low of $1.14 and a 52-week high of $7.20.

Wall Street Analysts Forecast Growth

ALDX has been the topic of several recent research reports. Wall Street Zen upgraded Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. BTIG Research reduced their price target on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a report on Monday, May 19th.

Institutional Trading of Aldeyra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ALDX. AQR Capital Management LLC raised its holdings in Aldeyra Therapeutics by 456.3% in the 1st quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company's stock valued at $2,257,000 after buying an additional 321,992 shares during the period. Jane Street Group LLC acquired a new position in Aldeyra Therapeutics in the 1st quarter valued at about $1,024,000. Acadian Asset Management LLC grew its position in Aldeyra Therapeutics by 7,402.7% in the 1st quarter. Acadian Asset Management LLC now owns 95,960 shares of the biotechnology company's stock valued at $551,000 after acquiring an additional 94,681 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Aldeyra Therapeutics in the 1st quarter valued at about $218,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.